# Nemtabrutinib, Bortezomib, and Rituximab for WM

> **NCT07464210** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 19 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** NEBULA

## Key facts

- **NCT ID:** NCT07464210
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2029-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07464210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07464210, "Nemtabrutinib, Bortezomib, and Rituximab for WM". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07464210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*